Osteoporosis Clinical Trial
Official title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women With Osteopenia Secondary to Glucocorticoids
Verified date | August 2021 |
Source | University of California, Davis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women with Osteopenia Secondary to Corticosteroids
Status | Completed |
Enrollment | 58 |
Est. completion date | March 31, 2021 |
Est. primary completion date | March 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 85 Years |
Eligibility | Inclusion Criteria: Subjects must meet all of the following criteria to be included in the study. 1. 20 - 85 years old 2. Receiving 5 - 40 mg/day prednisone, or equivalent of another GC (methylprednisolone 4 mg/day, or prednisone 10 mg every other day) for a minimum of 4 consecutive weeks prior to enrollment 3. Anticipated to continue to receive at least 5 mg/day prednisone or equivalent throughout study participation 4. T score = -1.0 in the femoral neck or total hip or lumbosacral spine. Only one result from one of these locations that is = -1.0 is required. For screening DXA, a DXA completed within 6 months of screening may be used; otherwise DXA must be completed within 4 weeks of screening visit. 5. Must be ambulatory and able to attend all appointments 6. Women must agree to use one of the following methods of birth control for the duration of the clinical trial: systemic hormonal contraceptive (oral, injected, transdermal), intrauterine device, double barrier (e.g., cervical cap or diaphragm with condom or spermicide). Men with female partners must agree to use double barrier contraception, unless their partner is using systemic hormonal contraceptives or has an intrauterine device. 7. In the opinion of the investigator, the concurrent medical conditions of the study subject are stable 8. Subject undergoing PET/CT scans must have the ability to lay motionless for up to 30-45 minutes 9. Anticipated to continue to receive all chronic medications without dose changes throughout study participation 10. Subjects undergoing PET/CT scans must have the ability to lay motionless for up to 30-45 minutes Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from the study: 1. Weight greater than the limit of the DXA table at the clinical site 2. History or concurrent conditions that might place the subject at increased risk, such as renal insufficiency (CKD 4 or 5), glomerulonephritis, atypical infections due to impaired immunity, hypersensitivity to multiple IV medications 3. History of or concurrent presence of medical conditions which might interfere with ability to participate for the duration of the study, such as clinically significant cardiovascular disease, uncontrollable hypertension, uncontrolled asthma, symptomatic pulmonary fibrosis, recent GI bleeding requiring transfusion, psychosis, substance abuse or hospital admission within 6 months of enrollment (except for elective procedures) 4. Prior use or current need for prohibited concomitant medications 5. Rheumatic disease with clinically significant renal or central nervous system involvement 6. History of deep vein thrombosis (DVT) along with taking any prophylaxis/treatment that occurred within the last 5 years 7. History of clinically significant atrial fibrillation and/or taking medications for its treatment and prevention 8. Unable or unwilling to comply with restrictions on alcohol 9. Previous hypersensitivity to alendronate 10. Any of the following on Screening laboratory tests: 1. Total calcium values outside the normal range (corrected if albumin < lower limit of normal (LLN)) 2. Phosphate level < LLN 3. 25-hydroxyvitamin D (25-OH Vitamin D) below 10ng/mL 4. TSH > upper limit of normal (ULN) 5. Hepatic enzymes (ALT, AST, GGT) > 1.5 X ULN 6. Creatinine clearance (eGRF) <35 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula 7. Hemoglobin <10 g/dL 8. Positive serology for HIV, Hepatitis B or C 9. Positive pregnancy test 10. Prolonged QTc interval (QTcF (Fredericia) of > 450 msec for men, > 470 msec for women) 11. Any other clinically significant laboratory value as judged by the investigator 11. Subject cannot enroll in MAD part of study until after 60 days of completing SAD part of study 12. Subjects undergoing PET/CT scans must not be breast-feeding 13. History of hypersensitivity to fluoride |
Country | Name | City | State |
---|---|---|---|
United States | West Coast Clinical Trials (WCCT) | Cypress | California |
United States | Metroplex Clinical Research Center | Dallas | Texas |
United States | Altoona Center for Clinical Research | Duncansville | Pennsylvania |
United States | Diablo Clinical Research | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
Nancy E. Lane, MD | California Institute for Regenerative Medicine (CIRM) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting Adverse events | Incidence of dose limiting or intolerable treatment related adverse events (AEs) including A serious drug-related adverse event in = 1 subject receiving LLP2A-Ale and/or Severe drug related adverse events in = 2 subjects receiving LLP2A-Ale | Duration of the Study, average of 4 years | |
Secondary | Severe infusion reactions | Fever, myalgia, nausea/vomit, headache, flu like symptoms in = 2 subjects receiving LLP2A-Ale | Duration of the study, average of 4 years | |
Secondary | Grade 2 elevated creatinine | serum creatinine greater than 1.5 - 3.0 x baseline; greater than 1.5 - 3.0 x upper limit of normal (CTCAE v4.0) in = 1 patient. | Duration of the study, average of 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06287502 -
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
|
N/A | |
Completed |
NCT03822078 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
|
Phase 1 | |
Recruiting |
NCT05845021 -
Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04736693 -
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
|
||
Not yet recruiting |
NCT06431867 -
Primary Care Management of Osteoporosis in Older Women
|
||
Completed |
NCT02922478 -
Role of Comorbidities in Chronic Heart Failure Study
|
||
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Recruiting |
NCT02635022 -
Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
|
||
Active, not recruiting |
NCT02617303 -
Prevention of Falls and Its Consequences in Elderly People
|
N/A | |
Completed |
NCT02566655 -
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis
|
Phase 1 | |
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Completed |
NCT03420716 -
Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women
|
N/A | |
Not yet recruiting |
NCT02223572 -
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
|
N/A | |
Not yet recruiting |
NCT01854086 -
Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday
|
N/A | |
Completed |
NCT02003716 -
DeFRA Questionnaire as an Anamnestic Form
|
N/A | |
Unknown status |
NCT01913834 -
Nasally and sc Administered Teriparatide in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01757340 -
Calorie Restriction With Leucine Supplementation
|
N/A | |
Completed |
NCT01694784 -
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
|
N/A |